Oncolytics Biotech (ONCY) to Release Quarterly Earnings on Thursday

Oncolytics Biotech (NASDAQ:ONCY) is set to release its earnings data after the market closes on Thursday, May 9th. Analysts expect Oncolytics Biotech to post earnings of ($0.09) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Oncolytics Biotech (NASDAQ:ONCY) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.07. On average, analysts expect Oncolytics Biotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oncolytics Biotech Trading Up 0.8 %

Shares of NASDAQ:ONCY opened at $1.19 on Wednesday. Oncolytics Biotech has a 12-month low of $0.88 and a 12-month high of $3.39. The stock’s 50-day moving average price is $1.07 and its 200-day moving average price is $1.24. The stock has a market capitalization of $89.75 million, a P/E ratio of -3.97 and a beta of 1.91.

Analyst Ratings Changes

ONCY has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Oncolytics Biotech in a report on Wednesday, February 14th. Raymond James initiated coverage on shares of Oncolytics Biotech in a research note on Thursday, April 4th. They set an “outperform” rating and a $3.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Oncolytics Biotech in a research note on Friday, January 12th.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.